The New Alzheimer’s Drug: Why Approval May Represent a Setback, and What Things May Have the Power of Prevention.

Home » The New Alzheimer’s Drug: Why Approval May Represent a Setback, and What Things May Have the Power of Prevention.
The New Alzheimer’s Drug: Why Approval May Represent a Setback, and What Things May Have the Power of Prevention.

Our medical system loves drugs that treat diseases. People with a disease are highly motivated to spend money and are willing to expose themselves to a risk in the hope of a cure. Unfortunately this new drug for Alzheimer’s, Aduhelm, comes at enormous price tag of over $50,000 per year, and does not cure dementia. In addition it’s been shown to have some very serious side effects. Nevertheless, it achieved FDA approval.

In this episode we discussed why this can be such a setback for dementia treatment. The focus becomes redirected away from prevention and toward passive hope of a cure. We also discuss some of the cross-cultural rates of dementia and look at the theories why some countries have such low rates. We highlight environmental factors such as iron, copper, lead and look at the correlation with hormones and dementia. For anybody with a desire to protect their brain, this podcast is essential listening.

Leave a Reply

Your email address will not be published.